Agouron to acquire combinatorial chemistry firm Alanex for $62 mil. in stock.
Executive Summary
AGOURON ACQUISITION OF ALANEX VALUES COMBINATORIAL CHEMISTRY FIRM AT ABOUT $62 MIL. based upon Agouron's stock price as of the April 28 signing of a definitive agreement. Agouron will acquire privately-held Alanex for 1 mil. shares of newly-issued stock; Agouron stock closed April 28 at $62 per share. The stock transaction allows Agouron to take advantage of its recent run-up in valuation related to the review and approval of its HIV therapy Viracept ("The Pink Sheet" March 17, T&G-1). The companies expect the transaction to close within 30 days.